A New Look for Our Website

The UR Ventures web site underwent a minor update last week. We have simplified navigation within the site, hopefully making the things you’re looking for a little easier to find.

As always, we welcome your feedback. Send comments and suggestions to the e-mail link, below.

Rochester and Cornell Team Up for Upstate Health Sciences Symposium

2014-Upstate Health Symposium

Eighty faculty and students from the University of Rochester and Cornell converged in Ithaca on Tuesday, 6 May 2014 for the Upstate New York Health Sciences Symposium and Technology Showcase. Attendees heard presentations from Cancer Biology and Neurobiology researchers and later mingled among more than two dozen posters detailing cutting-edge research being conducted at the two universities.

Telephus Aims to Tame Biofilms in Implantable Devices

BIOWORLD TODAY, 21 April 2014

By Marie Powers, Staff Writer

In Greek mythology, Telephus was a son of Heracles who received a wound in battle that would not heal until he returned to the Greek warrior, Achilles, who had inflicted the injury. He was healed by the very spear that had pierced him.

Real life is decidedly more complicated, but the fable is an apt metaphor for Telephus Medical LLC, which is developing a first-in-class humanized monoclonal antibody to prevent Staphylococcus reinfection and osteomyelitis in patients following total hip or knee replacement surgery. The company’s technology is designed to prevent the early events that drive the formation of antibiotic-resistant biofilm infections on implanted medical devices, which today require additional, revision surgery.

<--more-->

Wegman Foundation Donates $17 Million for Children’s Hospital and Institute for Data Science

Today, University of Rochester President Joel Seligman announced two extraordinary gifts from The Wegman Family Charitable Foundation (WFCF): a $10 million lead gift to the University’s Institute for Data Science and a $7 million gift to support Golisano Children’s Hospital. Together with previous gifts to several programs across the University campuses, today’s announcement brings to $20 million the WFCF’s total contributions to the University’s comprehensive campaign. In recognition of this support for the Institute for Data Science, the Institute’s new landmark building will bear the Wegmans name.

<--more-->

Finding Points to Possible New Parkinson’s Therapy

A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease.  These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.
Read More

iCardiac Technologies Partners with Norwest Venture Partners to Accelerate Growth

Palo Alto, CA – March 6, 2014 — iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, today announced a partnership transaction with Norwest Venture Partners (NVP), a global, multi-stage investment firm with $3.7 billion in capital under management. iCardiac will leverage the extensive strategic resources NVP has to offer to aggressively pursue significant growth opportunities and serve the rapidly growing needs of its pharmaceutical and medical device clients worldwide. Also as part of today’s announcement, two of NVP’s healthcare investment leaders, Dr. Ryan Harris and Dr. Robert Mittendorff, will join the Company’s board of directors.

The average cost to develop a new drug is about $1.2B and requires 10 to 15 years of development time.* iCardiac’s unique and proprietary technology allows CROs and pharmaceutical sponsors to obtain cardiac safety assessment results with less variance, resulting in smaller sample sizes and less development time. iCardiac is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. It currently serves seven of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.

–more–

SRO at UVANY Venture Forum

UVANY Forum March 2014

More than 150 entrepreneurs and venture capitalists from throughout New York State gathered at Brighton’s ARTISANworks Tuesday evening to network and to hear some Rochester success stories. Organized by the Upstate Venture Association of New York (UVANY), the event featured an introductory presentation on “The New Rochester” by Richard Glaser and an interactive panel discussion featuring Mike Totterman (iCardiac), David Chauncey (vNomics), Tim Wilson (Arnold Magnetics), and Chris Modesti (Biomaxx). The panel was moderated by Will Hoy (Secrest & Emery). The venue perfectly captured the energy and creativity present in the room. The picture, above, was taken seconds before the UR Ventures banner stand noisily imploded.